



(12) Translation of
European patent specification

(11) NO/EP 3851107 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/5377 (2006.01)
A61P 25/24 (2006.01)
C07D 471/04 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2022.12.27
(80)	Date of The European Patent Office Publication of the Granted Patent	2022.10.19
(86)	European Application Nr.	21154665.0
(86)	European Filing Date	2013.05.24
(87)	The European Application's Publication Date	2021.07.21
(30)	Priority	2012.05.25, US, 201261651669 P 2012.08.20, US, 201261691083 P 2012.10.19, US, 201261715907 P 2013.02.01, US, 201361759520 P 2013.03.14, US, 201361781629 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(62)	Divided application	EP3590517, 2013.05.24
(73)	Proprietor	Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, CA 94025, USA
(72)	Inventor	HUNT, Hazel, Edenderry House Bracken Close, Storrington West, Sussex, Storbritannia JOHNSON, Tony, 8/9 Spire Green Centre Flex Meadow, Harlow, Essex, Storbritannia RAY, Nicholas, 8/9 Spire Green Centre Flex Meadow, Harlow, Essex, Storbritannia WALTERS, Iain, BioCity Pennyfoot Street, Nottingham, Nottinghamshire, Storbritannia
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge


(54)	Title	HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS
(56)	References Cited:	WO-A1-2012/027702 WO-A1-2005/087769

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

EP3851107

Patentkrav

1. Farmasøytisk sammensetning omfattende en forbindelse av formel (I) og en farmasøytisk akseptabel eksipiens, for anvendelse i en fremgangsmåte for behandling av kreft ved modulering av en glukokortikoidreseptor, idet forbindelsen har formelen:



hvor

R^1 er en heteroarylring som har fra 5 til 6 ringelementer og fra 1 til 4 heteroatomer som hvert uavhengig velges fra gruppen bestående av N, O og S, valgfritt substituert med 1-4 grupper som hver uavhengig velges fra R^{1a} ; hver R^{1a} velges uavhengig fra gruppen bestående av hydrogen, C_{1-6} -alkyl, halogen, C_{1-6} -haloalkyl, C_{1-6} -alkoksy, C_{1-6} -haloalkoksy, -CN, N-oksid, C_{3-8} -sykloalkyl og C_{3-8} -heterosykloalkyl;

ring J velges fra gruppen bestående av en sykloalkylring, en heterosykloalkylring, en arylring og en heteroarylring, hvor heterosykloalkyl- og heteroarylringene har fra 5 til 6 ringelementer og fra 1 til 4 heteroatomer som hvert uavhengig velges fra gruppen bestående av N, O og S;

hver R^2 velges uavhengig fra gruppen bestående av hydrogen, C_{1-6} -alkyl, halogen, C_{1-6} -haloalkyl, C_{1-6} -alkoksy, C_{1-6} -haloalkoksy, C_{1-6} -alkyl- C_{1-6} -alkoksy, -CN, -OH, - $NR^{2a}R^{2b}$, - $C(O)R^{2a}$, - $C(O)OR^{2a}$, - $C(O)NR^{2a}R^{2b}$, - SR^{2a} , - $S(O)R^{2a}$, - $S(O)_2R^{2a}$, C_{3-8} -sykloalkyl og C_{3-8} -heterosykloalkyl, hvor heterosykloalkylgruppene valgfritt substitueres med 1-4 R^{2c} -grupper;

alternativt kombineres to R^2 -grupper som er forbundet med det samme karbon, for å danne en okso-gruppe (=O);

alternativt kombineres to R^2 -grupper for å danne en heterosykloalkylring som har fra 5 til 6 ringelementer og fra 1 til 3 heteroatomer som hvert uavhengig velges fra gruppen bestående av N, O og S, hvor heterosykloalkylringen valgfritt substitueres med fra 1 til 3 R^{2d} -grupper;

R^{2a} og R^{2b} velges hver uavhengig fra gruppen bestående av hydrogen og C_{1-6} -alkyl;

EP3851107

- hver R^{2c} velges uavhengig fra gruppen bestående av hydrogen, halogen, hydroksey, C_{1-6} -alkoksy, C_{1-6} -haloalkoksy, -CN og $-NR^{2a}R^{2b}$;
- hver R^{2d} velges uavhengig fra gruppen bestående av hydrogen og C_{1-6} -alkyl, eller to R^{2d} -grupper som er festet til det samme ringatom, kombineres for å danne (=O);
- 5 R^3 velges fra gruppen bestående av fenyl og pyridyl, hver valgfritt substituert med 1-4 R^{3a} -grupper;
- hver R^{3a} velges uavhengig fra gruppen bestående av hydrogen, halogen og C_{1-6} -haloalkyl;
- 10 n i senket skrift er et heltall fra 0 til 3; eller et salt derav.

2. Farmasøytisk sammensetning for anvendelse ifølge krav 1, hvor

- 15 R^1 er en heteroarylring som har fra 5 til 6 ringelementer og fra 1 til 4 heteroatomer som hvert uavhengig velges fra gruppen bestående av N, O og S, valgfritt substituert med 1-4 grupper som hver uavhengig velges fra R^{1a} ;
- hver R^{1a} velges uavhengig fra gruppen bestående av hydrogen, C_{1-6} -alkyl, halogen, C_{1-6} -haloalkyl, C_{1-6} -alkoksy, C_{1-6} -haloalkoksy, -CN, C_{3-8} -sykloalkyl og C_{3-8} -heterosykloalkyl;
- 20 ring J velges fra gruppen bestående av en sykloalkylring, en heterosykloalkylring, en arylring og en heteroarylring, hvor heterosykloalkyl- og heteroarylringene har fra 5 til 6 ringelementer og fra 1 til 3 heteroatomer som hvert uavhengig velges fra gruppen bestående av N, O og S;
- hver R^2 velges uavhengig fra gruppen bestående av hydrogen, C_{1-6} -alkyl, halogen, C_{1-6} -haloalkyl, C_{1-6} -alkoksy, C_{1-6} -haloalkoksy, -CN, $NR^{2a}R^{2b}$, C_{3-8} -sykloalkyl og C_{3-8} -heterosykloalkyl, hvor heterosykloalkylgruppene valgfritt substitueres med 1-4 R^{2c} -grupper;
- 25 R^{2a} og R^{2b} velges hver uavhengig fra gruppen bestående av hydrogen og C_{1-6} -alkyl;
- 30 hver R^{2c} velges uavhengig fra gruppen bestående av hydrogen, halogen, hydroksey, C_{1-6} -alkoksy, C_{1-6} -haloalkoksy, -CN og $NR^{2a}R^{2b}$;
- R^3 velges fra gruppen bestående av fenyl og pyridyl, hver valgfritt substituert med 1-4 R^{3a} -grupper;

EP3851107

hver R^{3a} velges uavhengig fra gruppen bestående av hydrogen, halogen og C_{1-6} -haloalkyl; og

n i senket skrift er et heltall fra 0 til 3.

5 **3. Farmasøytisk sammensetning for anvendelse ifølge krav 1 eller 2, hvor:**

(a) R^1 er en heteroarylring som har fra 5 til 6 ringelementer og fra 1 til 3 heteroatomer som hvert uavhengig velges fra gruppen bestående av N, O og S, valgfritt substituert med 1-4 grupper som hver uavhengig velges fra R^{1a} ;

10 hver R^{1a} velges uavhengig fra gruppen bestående av hydrogen, C_{1-6} -alkyl, C_{1-6} -haloalkyl og C_{1-6} -alkoksy;

ring J velges fra gruppen bestående av tetrahydrofuran, fenyl og pyridyl;

hver R^2 velges uavhengig fra gruppen bestående av hydrogen, C_{1-6} -alkyl, halogen, C_{1-6} -haloalkyl, C_{1-6} -alkoksy, C_{1-6} -haloalkoksy, -CN, $NR^{2a}R^{2b}$, C_{3-8} -sykloalkyl og C_{3-8} -heterosykloalkyl;

15 R^{2a} og R^{2b} velges hver uavhengig fra gruppen bestående av hydrogen og C_{1-6} -alkyl;

R^3 velges fra gruppen bestående av fenyl og pyridyl;

R^{3a} er F; og

n i senket skrift er 0 eller 1; eller

20 (b) R^1 er en heteroarylring som har fra 5 til 6 ringelementer og fra 1 til 3 heteroatomer som hvert uavhengig velges fra gruppen bestående av N, O og S, valgfritt substituert med 1-4 grupper som hver uavhengig velges fra R^{1a} ;

hver R^{1a} velges uavhengig fra gruppen bestående av hydrogen, C_{1-6} -alkyl, C_{1-6} -haloalkyl og C_{1-6} -alkoksy;

25 ring J velges fra gruppen bestående av fenyl og pyridyl;

hver R^2 velges uavhengig fra gruppen bestående av hydrogen, halogen, C_{1-6} -haloalkyl CN og C_{5-6} -heterosykloalkyl;

R^3 velges fra gruppen bestående av fenyl og pyridyl; og

R^{3a} er F.

30

4. Farmasøytisk sammensetning for anvendelse ifølge et hvilket som helst av kravene 1 til 3, hvor R^1 velges fra gruppen bestående av

EP3851107

- (a) pyrrol, pyrazol, imidazol, triazol, tetrazol, furan, oksazol, isoksazol, oksadiazol, tiofen, tiazol, isotiazol, tiadiazol, pyridin, pyrazin, pyrimidin og pyridazin;
- (b) 2-pyrrol, 3-pyrrol, 3-pyrazol, 4-pyrazol, 5-pyrazol, 2-imidazol, 4-imidazol, 5-imidazol, 1,2,3-triazol-4-yl, 1,2,3-triazol-5-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,2,3,4-tetrazol-1-yl, 1,2,3,4-tetrazol-5-yl, 2-furan, 3-furan, 2-oksazol, 4-oksazol, 5-oksazol, 3-isoksazol, 4-isooksazol, 5-isooksazol, 1,2,4-oksadiazol-3-yl, 1,2,4-oksadiazol-5-yl, 1,2,5-oksadiazol-3-yl, 1,3,4-oksadiazol-2-yl, 2-tiofen, 3-tiofen, 2-tiazol, 4-tiazol, 5-tiazol, 3-isotiazol, 4-isotiazol, 5-isotiazol, 1,2,3-tiadiazol-4-yl, 1,2,3-tiadiazol-5-yl, 1,2,4-tiadiazol-3-yl, 1,2,4-tiadiazol-5-yl, 1,2,5-tiadiazol-3-yl, 1,3,4-tiadiazol-2-yl, 2-pyridin, 3-pyridin, 4-pyridin, pyrazin, 2-pyrimidin, 4-pyrimidin, 5-pyrimidin, 6-pyrimidin, 3-pyridazin, 4-pyridazin, 5-pyridazin og 6-pyridazin;
- (c) pyrazol, imidazol, triazol, furan, oksazol, oksadiazol, tiofen, tiazol, pyridin, pyrazin og pyrimidin; eller
- (d) 1-pyrazol, 3-pyrazol, 4-pyrazol, 5-pyrazol, 2-imidazol, 4-imidazol, 5-imidazol, 1,2,3-triazol-4-yl, 1,2,3-triazol-5-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 2-furan, 3-furan, 2-oksazol, 4-oksazol, 5-oksazol, 1,2,4-oksadiazol-3-yl, 1,2,4-oksadiazol-5-yl, 1,2,5-oksadiazol-3-yl, 1,3,4-oksadiazol-2-yl, 2-tiofen, 3-tiofen, 2-tiazol, 4-tiazol, 5-tiazol, 2-pyridin, 3-pyridin, 4-pyridin, pyrazin, 2-pyrimidin, 4-pyrimidin, 5-pyrimidin og 6-pyrimidin.

5. Farmasøytisk sammensetning for anvendelse ifølge et hvilket som helst av kravene 1, 2 og 4, hvor hver R^{1a} velges uavhengig fra gruppen bestående av hydrogen, C₁₋₆-alkyl, C₁₋₆-haloalkyl, C₁₋₆-alkoksy og C₃₋₈-heterosykloalkyl.

6. Farmasøytisk sammensetning for anvendelse ifølge et hvilket som helst av kravene 1 til 5, hvor hver R^{1a} velges uavhengig fra gruppen bestående av hydrogen, metyl, etyl, trifluormetyl og metoksy.

7. Farmasøytisk sammensetning for anvendelse ifølge et hvilket som helst av kravene 1, 2 og 4 til 6, hvor ring J velges fra gruppen bestående av

(a) heterosykloalkyl, aryl og heteroaryl;

EP3851107

(b) aryl og heteroaryl; eller

(c) fenyl, pyridin, imidazol, pyrazol, triazol, tetrazol, tiadiazol, isotiazol, isoksazol, sykloheksyl, tetrahydrofuran og tetrahydro-2H-pyran.

5 **8.** Farmasøytisk sammensetning for anvendelse ifølge et hvilket som helst av kravene 1 til 7, hvor ring J er fenyl eller pyridyl.

9. Farmasøytisk sammensetning for anvendelse ifølge et hvilket som helst av kravene 1 og 4 til 8, hvor hver R² velges uavhengig fra gruppen bestående av

10 (a) hydrogen, C₁₋₆-alkyl, halogen, C₁₋₆-haloalkyl, C₁₋₆-alkoksy, C₁₋₆-haloalkoksy, C₁₋₆-alkyl-C₁₋₆-alkoksy, -CN, NR^{2a}R^{2b}, C(O)OR^{2a}, S(O)R^{2a}, C₃₋₈-sykloalkyl eller C₃₋₈-heterosykloalkyl, hvor heterosykloalkylgruppen har 5-6 ringelementer og 1 til 2 heteroatomer; eller

15 (b) hydrogen, metyl, etyl, propyl, isopropyl, F, Cl, -CF₃, CH₂OMe, OMe, OCHF₂, -CN, -NMe₂, -C(O)OH, -C(O)NMe₂, -S(O)₂Me, pyrrolidin, piperidin eller morfolin.

10. Farmasøytisk sammensetning for anvendelse ifølge et hvilket som helst av kravene 1 til 9, hvor R³ er 4-F-fenyl.

20

11. Farmasøytisk sammensetning for anvendelse ifølge krav 1, hvor forbindelsen velges fra gruppen bestående av:

(R)-(6-((6-klorpyridin-3-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

25 (R)-(6-((6-klorpyridin-3-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

30 (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(1-metyl-1H-imidazol-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-3-yl)metanon,

EP3851107

- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyl-1,3,4-oksadiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(oksazol-4-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(oksazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(furan-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiofen-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(oksazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyrimidin-2-yl)metanon,
- (R)-(6-((3,5-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metoksypyridin-2-yl)metanon,
- (R)-(4-etylpyridin-2-yl)(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metoksypyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((3-fluorbenzyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- ((4aR)-1-(4-fluorfenyl)-6-(((R/S)-tetrahydrofuran-2-yl)metyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-(o-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

EP3851107

- (R)-(6-((4-etylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 5 (R)-(6-((3-klorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3-metoksyfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((4-klor-3-fluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-
- 10 heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-metoksyfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((3-fluor-4-metylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-
- heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 15 (R)-(1-(4-fluorfenyl)-6-(fenylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((2-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-
- 20 heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((6-(trifluormetyl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-tosyl-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 25 (R)-(6-((4-fluor-3-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-4-((1-(4-fluorfenyl)-4a-pikolinoyl-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzonitril,
- (R)-(1-(4-fluorfenyl)-6-((6-metoksypyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-
- 30 heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((tetrahydro-2H-pyran-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

EP3851107

- (R)-(6-(sykloheksylsulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((1-etyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- (R)-(6-((3,5-dimetyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- (R)-(6-((1H-imidazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((6-morfolinopyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((6-(pyrrolidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-4-(((1-(4-fluorfenyl)-4a-(tiazol-2-karbonyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)metyl)benzonitril,
- (R)-(1-(4-fluorfenyl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(1-metyl-1H-1,2,4-triazol-5-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyrazin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((5-fluopyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

EP3851107

- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metoksypyridin-2-yl)metanon,
- 5 (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-5-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((5-fluopyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(pyrrolidin-1-yl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- 10 (R)-(1-(4-fluorfenyl)-6-((3-(pyrrolidin-1-yl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((5-(piperidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((5-(pyrrolidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- 15 (R)-(1-(4-fluorfenyl)-6-((6-(pyrrolidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- ((R)-1-(4-fluorfenyl)-6-((6-((R)-3-fluorpyrrolidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- 20 (R)-(1-(4-fluorfenyl)-6-((4-(pyrrolidin-1-yl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((5-(piperidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 25 (R)-(1-(4-fluorfenyl)-6-((5-(pyrrolidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,
- (R)-(6-((4-klorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 30 (R)-(1-(4-fluorfenyl)-6-((4-metoksi-3-metylfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

EP3851107

- (R)-(6-((3-klor-4-metoksyfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((3-fluor-4-metoksyfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 5 (R)-(6-((2-fluor-4-metylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,
- (R)-3-((1-(4-fluorfenyl)-4a-pikolinoyl-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzonitril,
- 10 (R)-(6-((4-(difluormetoksy)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3-(trifluormetoksy)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 15 (R)-(6-((3,5-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-tosyl-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,
- (R)-(6-((3-(difluormetoksy)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 20 (R)-(6-((3,4-dimetylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((3,5-dimetylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 25 (R)-(1-(4-fluorfenyl)-6-((6-metylpyridin-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 30 (R)-(6-((3-klor-4-fluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

EP3851107

- (R)-3-((1-(4-fluorfenyl)-4a-(4-metylpikolinoyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzonitril,
- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-imidazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(6-((3,5-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3-(metylsulfonyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-3-((1-(4-fluorfenyl)-4a-pikolinoyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzosyre,
- (R)-(1-(4-fluorfenyl)-6-((3-(metoksymetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-metyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oksazin-7-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((2,3,4-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((6-(trifluormetyl)pyridin-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((6-(trifluormetyl)pyridin-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

EP3851107

- (R)-(1-(4-fluorfenyl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- 5 (R)-(6-((1-etyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(6-((1,5-dimetyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- 10 (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- 15 (R)-(6-((4-fluor-3-metylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((4-metyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oksazin-7-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- 20 (R)-(6-((2,3-dihydrobenzofuran-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-5-((1-(4-fluorfenyl)-4a-(4-metylpikolinoyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)-1-metylindolin-2-on,
- 25 (R)-(1-(4-fluorfenyl)-6-((3-(metylsulfonyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(6-((1,3-dimetyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- 30

EP3851107

- (R)-(6-((2,3-dihydrobenzo[b][1,4]dioksin-6-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- 5 (R)-(6-((3-fluor-4-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(6-((3-fluor-4-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 10 (R)-3-((4a-(4-etylpikolinoyl)-1-(4-fluorfenyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzonitril,
- (R)-(4-etylpyridin-2-yl)(1-(4-fluorfenyl)-6-((6-(trifluormetyl)pyridin-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)metanon,
- 15 (R)-3-((1-(4-fluorfenyl)-4a-(4-metylpikolinoyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzosyre,
- (R)-(6-((3,5-dimetylisoksazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(6-((1-etyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 20 (R)-(1-fenyl-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((1,3-dimetyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- 25 (R)-(1-(4-fluorfenyl)-6-((2-(trifluormetyl)pyridin-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)pyridin-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- 30

EP3851107

- (R)-(1-(4-fluorfenyl)-6-((5-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- 5 (R)-(1-(4-fluorfenyl)-6-((2-(trifluormetyl)pyridin-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((4-klor-3-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((3-klor-4-metylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 10 (R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(2-(pyrrolidin-1-yl)pyridin-4-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- 15 (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((5-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- 20 (R)-3-((1-(4-fluorfenyl)-4a-(4-(trifluormetyl)pikolinoyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzonitril,
- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- 25 (R)-(6-((1,5-dimetyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- (R)-(6-((1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- 30 (R)-(1-(4-fluorfenyl)-6-((1-metyl-3-(trifluormetyl)-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

EP3851107

- (R)-(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- (R)-(1-(4-klorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- (R)-(6-((1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-1-(4-(trifluormetyl)fenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,
- (R)-(6-((1,2-dimetyl-1H-imidazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- (R)-(6-((1,2-dimetyl-1H-imidazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-imidazol-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- (R)-(6-((1-etyl-1H-imidazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- (R)-(6-((1-etyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-(2-metoksyetyl)-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(1-metyl-1H-pyrazol-4-yl)metanon,

EP3851107

- (R)-(1-(4-fluorfenyl)-6-((1-isopropyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((2-metyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- 5 (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-1,2,3-triazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- 10 (R)-(6-((2-etyl-2H-1,2,3-triazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((1-etyl-1H-1,2,3-triazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 15 (R)-(6-((1-etyl-1H-1,2,3-triazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((2-etyl-2H-1,2,3-triazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- 20 (R)-(6-((1-etyl-1H-1,2,3-triazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- (R)-(6-((1-etyl-1H-1,2,3-triazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- 25 (R)-(1-(4-fluorfenyl)-6-((2-propyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-1,2,3-triazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 30 (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

EP3851107

- (R)-(1-(4-fluorfenyl)-6-((2-propyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-1,2,3-triazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,
- 5 (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((2-isopropyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 10 (R)-(1-(4-fluorfenyl)-6-((1-isopropyl-1H-1,2,3-triazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-isopropyl-1H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((1-etyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,
- 15 (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,
- 20 (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- 25 (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-metoksyfenyl)-6-((3-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(6-((3-fluor-4-metyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- 30 (R)-(1-(4-fluorfenyl)-6-(fenylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,

EP3851107

- (R)-(6-((3-klorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metylpyridin-2-yl)metanon,
- 5 (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(6-metylpyridin-2-yl)metanon,
- (R)-(6-((4-fluor-3-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- 10 (R)-(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(6-((3-fluor-4-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- 15 (R)-(1-(4-fluorfenyl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metyltiazol-2-yl)metanon,
- (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- 20 (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,
- (R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- 25 (R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,
- (R)-(6-((4-klor-3-fluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,
- 30 (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,

EP3851107

- (R)-(6-((1,3-dimetyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,
- 5 (R)-(6-((1-etyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(6-((1-etyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- 10 (R)-(1-(4-fluorfenyl)-6-tosyl-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(1-metyl-1H-imidazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(1-metyl-1H-imidazol-2-yl)metanon,
- 15 (R)-3-((1-(4-fluorfenyl)-4a-pikolinoyl-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)-N,N-dimetylbenzamid,
- (R)-(6-((1-etyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- 20 (R)-pyridin-2-yl(1-(pyridin-3-yl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)metanon,
- (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-fenyl-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(3,4-difluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 25 (R)-(6-((3,5-difluor-4-metoksyfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((6-(dimetylamino)pyridin-3-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 30 (R)-5-((1-(4-fluorfenyl)-4a-pikolinoyl-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)-1-metylpyridin-2(1H)-on,

EP3851107

(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon og

(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-
 5 1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,
 eller salter derav.

12. Farmasøytisk sammensetning for anvendelse ifølge krav 1, hvor forbindelsen velges fra gruppen bestående av:

- 10 (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
 (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
 (R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-
 15 1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
 (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
 (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-
 20 yl)metanon,
 (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
 (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,
 25 (R)-(6-((3-fluor-4-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
 (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
 30 (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

EP3851107

(R)-(6-((1-etyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon, eller

5 (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon.

10 **13.** Farmasøytisk sammensetning for anvendelse ifølge et hvilket som helst av kravene 1 til 12 for anvendelse i en fremgangsmåte for behandling av benkreft, brystkreft, prostatakreft, eggstokkreft, hudkreft, hjernekreft, blærekreft, livmorhalskreft, leverkreft, lungekreft, leukemi, lymfom eller nevroblastom.

14. Farmasøytisk sammensetning for anvendelse ifølge et hvilket som helst av kravene 1 til 13 for anvendelse med et ytterligere antineoplastisk middel.

15 **15.** Farmasøytisk sammensetning for anvendelse ifølge krav 14, hvor det ytterligere antineoplastiske middel velges blant taksaner, taksol, docetaksel, paclitaxel, actinomycin, antracykliner, doxorubicin, daunorubicin, valrubicin, bleomycin og cisplatin.